Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 09, 2015

Alternating Sunitinib and Everolimus Is Not Efficacious As First-Line Therapy for aRCC

Annals of Oncology

 

Additional Info

Annals of Oncology
EVERSUN: A Phase 2 Trial of Alternating Sunitinib and Everolimus as First Line Therapy for Advanced Renal Cell Carcinoma
Ann. Oncol 2015 Feb 20;[EPub Ahead of Print], ID Davis, A Long, S Yip, D Espinoza, JF Thompson, G Kichenadasse, M Harrison, RM Lowenthal, N Pavlakis, A Azad, G Kannourakis, C Steer, D Goldstein, J Shapiro, R Harvie, L Jovanovic, AL Hudson, CC Nelson, MR Stockler, A Martin

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading